Literature DB >> 18827186

cIAP1-dependent TRAF2 degradation regulates the differentiation of monocytes into macrophages and their response to CD40 ligand.

Alban Dupoux1, Jessy Cartier, Séverine Cathelin, Rodolphe Filomenko, Eric Solary, Laurence Dubrez-Daloz.   

Abstract

Peripheral blood monocytes are plastic cells that migrate to tissues and differentiate into various cell types, including macrophages, dendritic cells, and osteoclasts. We have described the migration of cellular inhibitor of apoptosis protein 1 (cIAP1), a member of the IAP family of proteins, from the nucleus to the Golgi apparatus in monocytes undergoing differentiation into macrophages. Here we show that, once in the cytoplasm, cIAP1 is involved in the degradation of the adaptor protein tumor necrosis factor receptor-associated factor 2 (TRAF2) by the proteosomal machinery. Inhibition of cIAP1 prevents the decrease in TRAF2 expression that characterizes macrophage formation. We demonstrate that TRAF2 is initially required for macrophage differentiation as its silencing prevents Ikappa-Balpha degradation, nuclear factor-kappaB (NF-kappaB) p65 nuclear translocation, and the differentiation process. Then, we show that cIAP1-mediated degradation of TRAF2 allows the differentiation process to progress. This degradation is required for the macrophages to be fully functional as TRAF2 overexpression in differentiated cells decreases the c-Jun N-terminal kinase-mediated synthesis and the secretion of proinflammatory cytokines, such as interleukin-8 and monocyte chemoattractant protein 1 (MCP-1) in response to CD40 ligand. We conclude that TRAF2 expression and subsequent degradation are required for the differentiation of monocytes into fully functional macrophages.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18827186      PMCID: PMC2951832          DOI: 10.1182/blood-2008-02-137919

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB.

Authors:  Hasem Habelhah; Shoichi Takahashi; Ssang-Goo Cho; Takayuki Kadoya; Toshiki Watanabe; Ze'ev Ronai
Journal:  EMBO J       Date:  2004-01-08       Impact factor: 11.598

2.  Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation.

Authors:  Mariola Fotin-Mleczek; Frank Henkler; Angelika Hausser; Heike Glauner; Dierk Samel; Angela Graness; Peter Scheurich; Davide Mauri; Harald Wajant
Journal:  J Biol Chem       Date:  2003-10-13       Impact factor: 5.157

3.  A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha.

Authors:  Eric D Tang; Cun-Yu Wang; Yue Xiong; Kun-Liang Guan
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

4.  CD154 activates macrophage antimicrobial activity in the absence of IFN-gamma through a TNF-alpha-dependent mechanism.

Authors:  Rosa M Andrade; Matthew Wessendarp; Carlos S Subauste
Journal:  J Immunol       Date:  2003-12-15       Impact factor: 5.422

5.  Receptor interacting protein is ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in vitro.

Authors:  Sun-Mi Park; Jong-Bok Yoon; Tae H Lee
Journal:  FEBS Lett       Date:  2004-05-21       Impact factor: 4.124

Review 6.  The signaling adaptors and pathways activated by TNF superfamily.

Authors:  Paul W Dempsey; Sean E Doyle; Jeannie Q He; Genhong Cheng
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

7.  Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2.

Authors:  Barbara Vischioni; Giuseppe Giaccone; Simone W Span; Frank A E Kruyt; Jose A Rodriguez
Journal:  Exp Cell Res       Date:  2004-08-15       Impact factor: 3.905

8.  Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal-mediated event.

Authors:  Stéphanie Plenchette; Séverine Cathelin; Cédric Rébé; Sophie Launay; Sylvain Ladoire; Olivier Sordet; Tibor Ponnelle; Najet Debili; Thi-Hai Phan; Rose-Ann Padua; Laurence Dubrez-Daloz; Eric Solary
Journal:  Blood       Date:  2004-06-08       Impact factor: 22.113

9.  A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor.

Authors:  M Rothe; S C Wong; W J Henzel; D V Goeddel
Journal:  Cell       Date:  1994-08-26       Impact factor: 41.582

10.  Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling.

Authors:  Bruce S Hostager; Sokol A Haxhinasto; Sarah L Rowland; Gail A Bishop
Journal:  J Biol Chem       Date:  2003-09-04       Impact factor: 5.157

View more
  22 in total

1.  Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation.

Authors:  Chao Zheng; Venkataraman Kabaleeswaran; Yaya Wang; Genhong Cheng; Hao Wu
Journal:  Mol Cell       Date:  2010-04-09       Impact factor: 17.970

2.  Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor.

Authors:  Fanny Pilot-Storck; Emilie Chopin; Jean-François Rual; Anais Baudot; Pavel Dobrokhotov; Marc Robinson-Rechavi; Christine Brun; Michael E Cusick; David E Hill; Laurent Schaeffer; Marc Vidal; Evelyne Goillot
Journal:  Mol Cell Proteomics       Date:  2010-04-05       Impact factor: 5.911

3.  Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription.

Authors:  Jessy Cartier; Jean Berthelet; Arthur Marivin; Simon Gemble; Valérie Edmond; Stéphanie Plenchette; Brice Lagrange; Arlette Hammann; Alban Dupoux; Laurent Delva; Béatrice Eymin; Eric Solary; Laurence Dubrez
Journal:  J Biol Chem       Date:  2011-06-08       Impact factor: 5.157

4.  The deubiquitinating enzyme USP48 stabilizes TRAF2 and reduces E-cadherin-mediated adherens junctions.

Authors:  Shuang Li; Dan Wang; Jing Zhao; Nathaniel M Weathington; Dong Shang; Yutong Zhao
Journal:  FASEB J       Date:  2017-09-05       Impact factor: 5.191

5.  Comparative analysis of nonaspanin protein sequences and expression studies in zebrafish.

Authors:  Benoist Pruvot; Véronique Laurens; Françoise Salvadori; Eric Solary; Laurent Pichon; Johanna Chluba
Journal:  Immunogenetics       Date:  2010-09-04       Impact factor: 2.846

Review 6.  Molecular basis of NF-κB signaling.

Authors:  Johanna Napetschnig; Hao Wu
Journal:  Annu Rev Biophys       Date:  2013-03-11       Impact factor: 12.981

7.  Structural basis for the lack of E2 interaction in the RING domain of TRAF2.

Authors:  Qian Yin; Betty Lamothe; Bryant G Darnay; Hao Wu
Journal:  Biochemistry       Date:  2009-11-10       Impact factor: 3.162

8.  TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis.

Authors:  James E Vince; Delara Pantaki; Rebecca Feltham; Peter D Mace; Stephanie M Cordier; Anna C Schmukle; Angelina J Davidson; Bernard A Callus; Wendy Wei-Lynn Wong; Ian E Gentle; Holly Carter; Erinna F Lee; Henning Walczak; Catherine L Day; David L Vaux; John Silke
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

9.  The enigma of RIPK1 in the liver: More than just a kinase.

Authors:  Mihael Vucur; Anne T Schneider; Jérémie Gautheron; Tom Luedde
Journal:  Mol Cell Oncol       Date:  2017-03-22

10.  Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways.

Authors:  Fabrizio Montecucco; Maria Bertolotto; Luciano Ottonello; Alessandra Quercioli; François Mach; Franco Dallegri
Journal:  J Biomed Biotechnol       Date:  2009-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.